Jyong Biotech Ltd. (NASDAQ:MENS) Sees Significant Increase in Short Interest
by Scott Moore · The Cerbat GemJyong Biotech Ltd. (NASDAQ:MENS – Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 649,057 shares, an increase of 157.2% from the December 15th total of 252,374 shares. Approximately 0.9% of the company’s stock are short sold. Based on an average daily trading volume, of 3,554,772 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 3,554,772 shares, the short-interest ratio is presently 0.2 days. Approximately 0.9% of the company’s stock are short sold.
Institutional Trading of Jyong Biotech
A hedge fund recently bought a new stake in Jyong Biotech stock. BNP Paribas Financial Markets purchased a new position in Jyong Biotech Ltd. (NASDAQ:MENS – Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,698 shares of the company’s stock, valued at approximately $67,000.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.
Check Out Our Latest Analysis on Jyong Biotech
Jyong Biotech Trading Up 0.3%
NASDAQ:MENS opened at $3.47 on Friday. Jyong Biotech has a one year low of $2.60 and a one year high of $67.00. The company has a fifty day moving average price of $18.75 and a 200 day moving average price of $32.70.
About Jyong Biotech
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.